Mycoplasma Diagnostics Market, DNA Staining, and Microbial Culture Techniques; End Users Hospitals, Diagnostic Laboratories, and Clinics Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 2024
News Article | May 9, 2017
Global Mycoplasma Diagnostics Market: Scope of the Report The market overview section of the report explores the market dynamics such as drivers, restraints, and opportunities that currently have a strong impact on the global mycoplasma diagnostic market and could influence the market in the near future. Market attractiveness analysis has been provided in all the sections of the report in order to explain the intensity of competition in the market across different products/techniques /end-users/geographies. The competitive scenario among different market players is evaluated through market share analysis in the competition landscape section of the report. The section also includes completion matrix that analyzes the competition among some of the top global players operating in the market. All these factors would help market players to take strategic decisions in order to strengthen their positions and expand their shares in the global market. Global Mycoplasma Diagnostics Market: Key Segments The global mycoplasma diagnostics market has been studied based on major product segments, technique segment, their end-users, and regional as well as national markets. Based on product type, the global market has been categorized into three major 4 segments: Kits & reagents, instruments, software's & services. On the basis of technology the mycoplasma diagnostics market are classified as PCR (Polymerase Chain Reaction), Immunoassay (ELISA, RIA), DNA staining, Microbial Culture Techniques, Others. On the basis of end users the market has been classified as hospitals, diagnostic laboratories, clinics and others. The market for these segments has been extensively analyzed based on their utility, effectiveness, sales, and geographic presence. Market revenue in terms of US$ Mn and market volume in terms of units for the period from 2014 to 2024 along with the compound annual growth rate (CAGR %) from 2016 to 2024 are provided for all segments, considering 2015 as the base year. Global Mycoplasma Diagnostics Market: Regional Outlook Geographically, the mycoplasma diagnostic market has been segmented into five regions: North America, Europe, Asia Pacific, Europe, Middle East & Africa (MEA), and Latin America. Each regional market for microfluidics has been further categorized into major product, technology, and end-user segments considered within the scope of the study. Key country (U.S., Canada, Japan, Germany, France, U.K., Canada, China, Brazil, Mexico, India, etc.) market revenues have also been provided in different regional sections within the report. Market revenue in terms of US$ Mn for the period from 2014 to 2024 along with CAGR % from 2016 to 2024 are provided for all the regions and nations considering 2015 as the base year. Companies Mentioned in the Report The report also profiles key players operating in the microfluidics market based on various attributes such as company details, SWOT analysis, strategic overview, financials, and business overview. Major players profiled in this report include F. Hoffmann-La Roche Ltd., Agilent Technologies, Sartorius Stedim BioOutsource Limited, Savyon Diagnostics, Takara Bio Inc. (Takara Holding Company Inc.), Lonza Group, Merck KGaA, and Charles River Laboratories International, Inc. among others. The global mycoplasma diagnostics market is segmented as follows: Mycoplasma Diagnostics Market, by Product Kits & Reagents Instruments Software & Services Mycoplasma Diagnostics Market, by Technology PCR Immunoassay ELISA RIA DNA staining Microbial Culture Techniques Others Mycoplasma Diagnostics Market, by End Users Hospitals Diagnostic Laboratories Clinics Others Global Multiplexed Diagnostics Market, by Region North America U.S. Canada Europe Germany U.K. France Italy Spain Rest of Europe Asia Pacific India China Japan Rest of Asia Pacific Latin America Brazil Mexico Rest of Latin America Middle East & Africa Saudi Arabia South Africa Download the full report: https://www.reportbuyer.com/product/4885785/ About Reportbuyer Reportbuyer is a leading industry intelligence solution that provides all market research reports from top publishers http://www.reportbuyer.com For more information: Sarah Smith Research Advisor at Reportbuyer.com Email: firstname.lastname@example.org Tel: +44 208 816 85 48 Website: www.reportbuyer.com To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/mycoplasma-diagnostics-market-dna-staining-and-microbial-culture-techniques-end-users---hospitals-diagnostic-laboratories-and-clinics---global-industry-analysis-size-share-growth-trends-and-forecast-2016---2024-300453774.html
Dan M.,E Wolfson Hospital |
Dan M.,Tel Aviv University |
Leshem Y.,Savyon Diagnostics Ltd. |
Yeshaya A.,Danielly Medical Center
Diagnostic Microbiology and Infectious Disease | Year: 2010
We compared the performance of a rapid vaginal yeast assay (Savvycheck) with that of microscopic examination of a Gram-stained smear and culture of vaginal discharge in detecting Candida spp. Two hundred thirty-one women with vaginal symptoms were studied prospectively. Vaginal specimens obtained from all participants were studied by the Savvycheck rapid yeast test, microscopic evaluation of Gram-stained vaginal smears, and yeast culture. Savvycheck rapid yeast test was positive in 79% of women with positive cultures and in 3.6% of women with negative cultures. The Savvycheck test detected yeasts in 93% of subjects with positive Gram stain and in 5.5% of subjects with negative Gram stain. The Savvycheck rapid yeast test showed 93% sensitivity, 95% specificity, and a 97% negative predictive value compared with the Gram stain. It revealed 79% sensitivity, 96% specificity, and an 87% negative predictive value compared with culture. The Savvycheck rapid yeast test can be used in the busy office instead of microscopy as a point-of-care tool for diagnosing vulvovaginal candidiasis. It can also reduce the need for yeast cultures in patients with vaginitis. © 2010 Elsevier Inc.
Dogruman-Al F.,Gazi University |
Turk S.,Gazi University |
Adiyaman-Korkmaz G.,Gazi University |
Hananel A.,Savyon Diagnostics Ltd |
And 7 more authors.
Parasitology Research | Year: 2014
Detection of Blastocystis is routinely performed by microscopy, culture, and formyl-ether (ethyl acetate) concentration technique (FECT). Yet, these methods require special skilled personnel, are time consuming, and often involve processing that may cause misdiagnosis. The aim of this work is to demonstrate the usefulness of a newly introduced ELISA test for the detection of Blastocystis antigens in stool samples (CoproELISATMBlastocystis, Savyon Diagnostics) as a proper alternative to currently used methods, especially microscopy. A cohort of 179 fresh/frozen clinical stool samples was tested by the ELISA test, and results were compared to consensus methods comprised of microscopic examination of Lugol’s iodine staining, culture, and immunofluorescence assay (IFA). The new ELISA test was able to detect fewer than 103 cells, recognized subtypes 1, 2, 3, and 5 (comprising >95 % of human Blastocystis infections), and exhibited similar reactivity when comparing formalin-preserved samples to fresh/frozen samples. The test demonstrated 92 % sensitivity, 87 % specificity, and 89 % accuracy when culture, and IFA or microscopy consensus results were taken as reference. When the consensus was comprised of culture and IFA, the test demonstrated sensitivity, specificity, and accuracy of 82, 86, and 84 %, respectively. In contrast, the sensitivity of Lugol staining microscopy was only 18 %. This work presents a unique ELISA test that provides an alternative to the use of microscopy, currently most widely used method. The test enables high-throughput screening and diagnosis of Blastocystis, adaptation to automatic procedures. © 2014, Springer-Verlag Berlin Heidelberg.